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The Laryngopharyngeal Reflux (LPR) physiopathology 
is still unknown. The Epidermal Growth Factor (EGF) is 
a biologically active salivary protein that aids in the rapid 
regeneration of the oropharyngeal and upper digestive tract 
mucosas. Salivary deficiency of this protein in patients with 
LPR has been demonstrated in previous studies. Aim: To 
compare salivary EGF concentration in patients with LPR 
before and after treatment. Materials and Methods: In this 
prospective study twelve patients with GERD and moderate 
LPR were studied. Whole saliva samples were collected 
before and after treatment and salivary EGF concentration 
was determined using a commercially available ELISA kit 
(Quantikine ®). Results: There were eleven females and one 
male among the patients, the mean age was 49 years. The 
mean pre-treatment salivary EGF concentration was 2,867.6 
pg/mL and the mean post treatment EGF concentration was 
1,588.5 pg/mL. This difference was statistically significant 
(p=0.015). Discussion and Conclusions: Although salivary 
EGF concentrations are higher before LPR treatment, the 
concentration is still much lower than the mean salivary 
EGF concentration in normal individuals without LPR, 
which suggests a primary disorder of this defense factor in 
individuals with LPR.
Keywords: gastroesophageal reflux disease (gerd), epidermal 
growth factor (egf), chronic laryngitis, saliva.
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INTRODUCTION
Gastro-esophageal reflux disease (GERD) is the 
most prevalent digestive disorder of modern times, in the 
last decade it has been implicated in a number of laryn-
go-pharyngeal disorders1-17. This supraesophageal form 
of the GERD was called Laryngo-Pharyngeal Reflux (LPR) 
by Koufman et al. in 19947, not aiming at establishing its 
origin, but rather with the intent of stressing symptoms 
predominance and the alterations brought about to the 
laryngopharyngeal segment. Symptoms associated to the 
reflux are weekly reported by 3 to 6% of the individuals 
in the general population13,18,19. Notwithstanding, very little 
is known about the physiopathology of these supraglottic 
GERD presentations. 
It is interesting to notice how a large number of 
patients with laryngopharyngeal reflux (LPR), even those 
with more marked laryngeal findings, do not have eso-
phagitis or other signs of GERD in their digestive tract15-17. 
Certainly, the gastric and esophageal mucosal protection 
mechanisms have a decisive role in the capacity these 
organs have of withstanding mechanical and chemical 
aggression to which they are daily exposed, and many 
of these mechanisms are saliva-mediated15,20-27. Saliva has 
many organic and inorganic substances that contribute to 
this protection against physical and chemical attacks, and 
used for the maintenance of the mucosal lining, not only 
of the oral mucosa, but also that of the digestive tract20-26. 
Contradictory clinical findings and recent research reports 
suggest deficiencies in the defense capacity of this segment 
in GERD22-24 patients and, more specifically, in LPR15, 27-29.
One of the factors most responsible for homeostasis 
of the oral mucosa and the digestive tract is the saliva and 
its organic content. The Epidermal Growth Factor - EGF, is 
the salivary protein with the most action on epithelial re-
generation after physical and chemical aggression, because 
of its important capacity in replicating DNA and aiding in 
the neoangiogenesis of epithelial cells25. In a recent study, 
we proved that there is a significant EGF concentration 
reduction in saliva in individuals with LPR when com-
pared to normal individuals27. Our goal with the present 
investigation is to check and see if there are salivary EGF 
concentration alterations in the same individual with GERD 
and LPR before and after clinical treatment, in order to try 
and establish if the deficiency of this protection factor is 
primary (congenital) or secondary (acquired).
MATERIALS AND METHODS
Our series is made up of 12 individuals, eleven 
females and one male, with average age of 49 years (ran-
ging between 33 and 72 years), with clinical diagnosis 
of GERD confirmed by 24 hour two-channel esophageal 
pH-measurement, screened in an Otorhinolaryngology 
ward of a tertiary University Hospital. This research project 
was approved by the Ethics Committee of our Institution 
(Protocol # CEP 179/04). We only included in our study 
those patients who had endoscopic diagnosis of GERD, 
corroborated by 24hour two-channel pH-measures, who 
agreed to participate in the study after having been explai-
ned is goals, procedures used and risks involved. Exclusion 
criteria encompassed smoking, alcohol intake and expo-
sure to volatile chemical abrasive substances - because all 
these factors cause inflammation in the respiratory mucosa 
and may mimic the alterations seen in GERD. Moreover, 
we also excluded those patients who had used gastric 
secretion blocking agents, pro-kinetics, anti-acids or hor-
monal and non-hormonal anti-inflammatory agents in the 
14 days prior to their inclusion in the protocol, because 
these drugs impact the digestive tract mucosa and the gas-
tric secretion. We also excluded patients with larynx and 
pharynx pre-neoplastic or neoplastic lesions (either pre-
sent or previously treated). Individuals with intolerance to 
proton-pump inhibitors did not participate in the study. All 
participants answered a detailed questionnaire about their 
general health and GERD-related symptoms, their digestive 
and otorhinolaryngological manifestations15,16. They also 
underwent videolaryngoscopy exam with a 3.5mm Pentax 
flexible scope, which were recorded in a DVD by using 
the score established by Belafasky et al. in 2001 (Reflux 
Finding Score - RFS) (Figure 1)30. Nasal-fibro-laryngoscopy 
was carried out right at the start of the protocol (pre-tre-
atment exam) and after the end of treatment and disease 
control (post-treatment exam). As disease control we deem 
to be the resolution of the laryngopharyngeal symptoms 
and RFS improvement. The standardized treatment for all 
the patients was the use of a proton inhibiting drug in a 
full dose, before breakfast and before dinner during 16 
weeks. After this period, the patients were reassessed from 
the standpoint of clinical signs and symptoms of LPR, and 
a new saliva collection was carried out 7 days after the 
medication was interrupted. 
The participants of this study had two samples of 
their saliva collected during 15 minutes after a 12 hour 
fasting period, one pretreatment and another post-tre-
atment (harvested seven days after the drug treatment 
interruption). The patients were instructed not to use too-
thpaste on the sample-harvesting day, and all the samples 
were harvested in the same morning period in order to 
comply with circadian salivary production fluctuations28. 
The samples were immediately packed in ice, in order 
to avoid protein denaturation. To study the EGF salivary 
content, the total saliva supernatant material was used after 
being centrifuged for 10 minutes at room temperature at 
a speed of 5000-7000 revolutions per minute (RPM). This 
material was then transferred to another Falcon tube with 
a threaded cap and was stored at -70 degrees Celsius 
until its analysis. The samples received alpha-numerical 
identification. In order to determine the salivary EGF 
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concentration we used a commercially available ELISA kit 
for EGF dosing (Quantikine R) supplied by R&D Systems 
Inc., EUA. The EGF concentration was determined based 
on saliva protein concentration. We compared EGF sali-
vary concentrations before and after treatment, as well as 
correlations with symptoms improvement and laryngeal 
inflammatory findings.
Results were statistically analyzed and plotted by 
means of the Wilcoxon test, with a 95% significance le-
vel.
RESULTS
All subjects in the study had moderate LPR with 
daily laryngopharyngeal symptoms and an average RFS 
score of 21.4 points. After treatment, patients remained 
symptom less in both the laryngopharyngeal and digestive 
tracts, and the average RFS dropped 13 points (Table 1). 
Pre-treatment average EGF salivary concentration was of 
2,867.6pg/mL and the post treatment and disease control 
concentration was of 1,588.5pg/mL, and such difference 
was statistically significant (p=0.015) (Table 1). When we 
compare the average EGF salivary concentration of this 
sample with the EGF salivary concentration of a previou-
sly established population of normal adults15,27, we notice 
that normal individuals presented in average more sali-
vary EGF than individuals with LPR (7,085pg/mL versus 
Figure 1. Laryngopharyngeal reflux-caused-inflammatory process 
intensity scale, based on videolaryngoscopy signs (varies from zero 
to 28).
    1) Subglottic edema (pseudo-groove) 2 = present
    2) Ventricle obliteration 2 = partial 
    (by ventricular and vocal folds edema) 4 = complete
    3) Vocal folds edema 1 = mild
   2 = moderate
3 = intense
4 = polypoid
    4) Diffuse larynx edema 1 = mild
    2 = moderate
3 = intense
4 = obstructive
5) Thickening (irregularity) on the posterior commisure 1 = mild    
    2 = moderate
3 = intense
4 = obstructive
6) Erythema/Hiperemia 2 = arytenoids only  
4 = Diffuse
7) Granuloma    2 = present
8) Thick endolaryngeal mucous    2 = present
Modified from Belafsky et al., 2001.
Table 1. Demographic and salivary EGF (Epidermal Growth Factor) concentration data of individuals in the study before and after treatment 
with IBP for 16 weeks.
Patient gender age (years) Initial RFS Final RFS PreEGF(pg/mL)) PostEGF (pg/mL)
1 F 36 22 13 1463,35 1071,25
2 M 54 21 14 1874,7 56
3 F 64 22 12 4717,05 2231,15
4 F 72 20 16 3006,65 2661,3
5 F 60 23 12 5337,3 365,75
6 F 33 22 14 1758,5 3316,15
7 F 46 22 12 2147,35 209,75
8 F 45 20 14 3986,3 2072,95
9 F 38 16 9 2243,65 303,7
10 F 45 24 16 2633,4 2370,35
11 F 52 24 12 1729,35 1119,2
12 F 47 21 12 3516,15 3288,2
average  49,33 21.4 13 2867,5 1588,5
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2,867.6pg/mL and 1,588.5pg/mL pre and post treatment, 
respectively). This difference between individuals without 
the disease and those with LPR was statistically significant 
(p=0.02) (Figure 2). There was no difference in data when 
the only male individual of the sample was excluded from 
the statistical analysis. Thus, we kept this patient’s data in 
the studied group.
out before the present one, have established salivary and 
digestive tract deficiencies of protection factors, such 
as EGF, in individuals with dyspeptic disease or reflux 
esophagitis21,22,25,26. More recently we have established 
a significant reduction in EGF salivary concentration in 
individuals with GERD chronic laryngitis when compared 
to a group of normal individuals15,16,27.
In the present study we found an EGF salivary con-
centration significantly higher in individuals during disease 
activity that dropped after the disease was controlled. This 
higher EGF salivary concentration during disease activity 
probably shows an attempt our body make in order to de-
fend itself from the chemical aggression to which it is being 
subjected. However, this significant difference in salivary 
concentration of such epithelium regenerator polypeptide 
between normal individuals and those with LPR suggest 
the possibility of primary deficiency in salivary production 
of this important defense factor, further reinforcing the 
greater susceptibility of some individuals in developing 
inflammatory alterations on the laryngopharyngeal mucosa 
after exposure to the chemical aggression caused by the 
gastroduodenal content reflux.
Both GERD and LPR are known to prevail in 
females3,6,8,15,16, and this explains why we have only one 
man in this series. Notwithstanding, the data of this single 
patient was kept because it was homogenous with those 
from the other female participants. The present study re-
ports on the preliminary results of a larger study aiming at 
better understanding the physiopathological factors related 
to this atypical form (but not so atypical for otorhinolaryn-
gologists) of Gastro-Esophageal Reflux Disease. If, in fact, 
this primary deficiency in organic defense mechanisms 
of the laryngopharyngeal segment is proven, we may fo-
resee much less aggressive and anti-physiologic ways to 
diagnose and treat Laryngopharyngeal Reflux. Despite our 
small sample, findings were highly significant, suggesting 
a strong correlation between EGF salivary concentration 
deficiency and LPR.
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